MedPath

Impact of clinical efficacy of probiotics in hemodialysis patients.

Not Applicable
Conditions
Chronic renal failure patients receiving hemodialysis
Registration Number
JPRN-UMIN000031365
Lead Sponsor
Tokyo Women's Medical University
Brief Summary

The ratio of CRP to albumin did not change before and after treatment in both groups. The serum phosphate levels in the Bio-Three group significantly decreased after 6-month treatment, while did not change in the placebo group. In a 16s rRNA gene-based sequencing protocol analysis, the ratio of Firmicutes, Actinomycetales and Neisseriaies significantly changed after 6 month treatment in the only probiotic group.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1 Patients who received peritoneal dialysis 2 Patients whose serum CRP levels were 1.0 mg/dl and over within 1 week 3 Patients who took ethical drugs including probiotics within 1 week 4 Patients with an infection or a sign of an infection within 1 week 5 Patients with an inflammatory disease or a sign of an inflammatory disease 6 Patients with a past history of hypersensitivity to BIO-THREE component 7 Patients considered as inadequate human subjects by the principal investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the changes of the ratio of CRP to albumin before and after administration of probiotics products.
Secondary Outcome Measures
NameTimeMethod
1. Intestinal flora (next generation sequence) 2. ALP isozyme 3. Serum level of ALP 4. The small intestine gas
© Copyright 2025. All Rights Reserved by MedPath